FDA Approves Drug for Treatment of DMD

By | April 3rd, 2017|information, research, trials|

Chantal Coles PhD NMDRC provides a Research Update... On September 19th last year the U.S Food and Drug Administration (FDA) approved the first [...]

Spinal Muscular Atrophy (SMA) Research Update

By | November 17th, 2016|atrophies, research, trials|

Spinal Muscular Atrophy (SMA) Research update and treatment - AUSTRALIA A research update by Prof. Monique Ryan Director, Department of Neurology Group Leader, [...]

Muscle Clinic

By | October 24th, 2016|

Muscle Clinic A world-first initiative, the MDA funded (we have invested in excess of $1.5 million) clinic is an initiative in which we [...]

Clinical trial of new steroid for DMD

By | July 23rd, 2016|

ReveraGen BioPharma has announced the start of a Phase 1 clinical trial of a new steroidal drug, VBP15, for Duchenne muscular dystrophy (DMD). [...]

Clinical trial results for Oculopharyngeal MD

By | July 23rd, 2016|

The results of a clinical trial have shown that transplanting cells from unaffected muscles into the throat may help with the swallowing difficulties [...]

Sarepta apply for approval of Duchenne MD drug

By | July 23rd, 2016|

Sarepta Therapeutics has issued a press release which gives an update on their plans for the development of exon skipping drug “eteplirsen”. Eteplirsen [...]

Spinal Muscular Atrophy An Overview

By | July 21st, 2016|

What Is Spinal Muscular Atrophy? Spinal muscular atrophy (SMA) is a genetic condition which affects the nerves that control muscle movement– the motor [...]

MDA’s Sponsorship of CINRG

By | September 27th, 2007|disorders, research|

MDA's Sponsorship of CINRG  The Cooperative International Neuromuscular Research Group, (CINRG), was formed in 1999 as the clinical research arm of the Duchenne [...]